毕得医药(688073) - 2025 Q1 - 季度财报

Financial Performance - In Q1 2025, the company achieved operating revenue of CNY 296,374,647.62, representing a year-on-year increase of 12.83% from CNY 262,669,977.50[5] - The net profit attributable to shareholders was CNY 30,693,093.12, up 17.71% compared to CNY 26,074,943.00 in the same period last year[6] - The net profit after deducting non-recurring gains and losses was CNY 28,075,051.47, reflecting a 10.40% increase from CNY 25,431,195.19[5] - Total revenue for Q1 2025 reached ¥296,374,647.62, an increase of 12.8% compared to ¥262,669,977.50 in Q1 2024[23] - Net profit for Q1 2025 was ¥30,693,093.12, compared to ¥26,074,943.00 in Q1 2024, representing a year-over-year increase of 17.5%[24] - The total comprehensive income for the first quarter of 2025 was CNY 31,417,192.67, compared to CNY 25,735,878.22 in the first quarter of 2024, representing an increase of approximately 22.5%[26] - Basic and diluted earnings per share for the first quarter of 2025 were CNY 0.34, up from CNY 0.29 in the same period last year, indicating an increase of about 17.2%[26] Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 85.27%, amounting to CNY 7,096,558.99, primarily due to increased procurement in response to anticipated changes in U.S. import tariff policies[10] - Cash inflows from operating activities for Q1 2025 totaled CNY 286,980,156.39, slightly higher than CNY 283,642,299.11 in Q1 2024, reflecting a growth of approximately 1.0%[28] - The net cash flow from operating activities decreased to CNY 7,096,558.99 in Q1 2025, down from CNY 48,167,499.32 in Q1 2024, a decline of about 85.3%[29] - Cash outflows from investment activities in Q1 2025 were CNY 838,293,599.56, significantly higher than CNY 2,307,488.30 in Q1 2024, indicating a substantial increase in investment spending[29] - The net cash flow from investment activities for Q1 2025 was negative at CNY -741,715,571.79, compared to CNY -945,983.29 in Q1 2024, showing an improvement in cash flow[29] - Cash inflows from financing activities in Q1 2025 amounted to CNY 231,501,858.62, a significant increase from CNY 39,751,310.37 in Q1 2024, representing a growth of approximately 481.5%[29] - The net cash flow from financing activities for Q1 2025 was CNY 184,721,660.79, compared to a negative CNY -37,126,744.60 in Q1 2024, indicating a positive turnaround[29] - The ending cash and cash equivalents balance for Q1 2025 was CNY 549,182,096.58, down from CNY 1,274,242,684.77 in Q1 2024, a decrease of approximately 56.9%[29] - The company reported a cash flow impact from exchange rate changes of CNY 2,458,750.34 in Q1 2025, compared to a negative impact of CNY -922,141.10 in Q1 2024, indicating a favorable currency effect[29] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,669,271,932.87, a 10.39% increase from CNY 2,418,035,118.40 at the end of the previous year[5] - Current liabilities rose to ¥593,692,231.04 in 2025, compared to ¥345,761,323.60 in 2024, indicating an increase of 71.7%[21] - The total equity attributable to shareholders increased to ¥2,033,370,876.60 in 2025 from ¥2,027,122,463.64 in 2024, a slight increase of 0.3%[22] Research and Development - Research and development expenses totaled CNY 15,144,994.42, accounting for 5.11% of operating revenue, down from 5.87% in the previous year[5] - Research and development expenses for Q1 2025 were ¥15,144,994.42, slightly down from ¥15,420,297.35 in Q1 2024[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,610[11] - The company has a total of 3,207,327 shares in its repurchase account, representing 3.53% of total shares[14] - The top ten shareholders hold a significant portion of the company's shares, with Ningbo Xinxin Venture Capital holding 5,019,806 shares, accounting for 5.52%[15] Strategic Developments - The company plans to increase its investment in Zhuhai Weibo Investment Co., Ltd. by ¥10,331.16 million, maintaining a 49% ownership stake[16] - The registered capital of Zhuhai Weibo Investment Co., Ltd. will increase from $4.17 million to $21.501 million following the capital increase[16] - The company intended to acquire 100% of Combi-Blocks, Inc. but failed to complete the transaction by the deadline of April 12, 2025[18] - The company has established a joint venture with Vivo Cypress X, Co. Limited and Weiwang (Suzhou) Health Industry Investment Fund to enhance its strategic development[15]